K161364 is an FDA 510(k) clearance for the BinaxNOW G6PD Test. Classified as Glucose-6-phosphate Dehydrogenase (erythrocytic), Screening (product code JBF), Class II - Special Controls.
Submitted by Alere Scarborough, Inc. (Scarborough, US). The FDA issued a Cleared decision on June 17, 2016 after a review of 31 days - a notably fast clearance cycle.
This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7360 - the FDA hematology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.
Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.